Unique ID issued by UMIN | UMIN000020386 |
---|---|
Receipt number | R000023540 |
Scientific Title | Acute Vasoreactivity Testing with Nicardipine in Patients with Pulmonary Arterial Hypertension |
Date of disclosure of the study information | 2015/12/28 |
Last modified on | 2015/12/28 16:14:55 |
Acute Vasoreactivity Testing with Nicardipine in Patients with Pulmonary Arterial Hypertension
Acute Vasoreactivity Testing with Nicardipine in Patients with Pulmonary Arterial Hypertension
Acute Vasoreactivity Testing with Nicardipine in Patients with Pulmonary Arterial Hypertension
Acute Vasoreactivity Testing with Nicardipine in Patients with Pulmonary Arterial Hypertension
Japan |
plumonary arterial hypertension
Cardiology |
Others
NO
Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
safety of acute vasoreactivity testing with nicardipine in PAH patients
Whether can acute vasoreactivity testing with nicardipine identify patients with sustained beneficial response to oral calcium channel blockers.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Medicine |
Nicardipine was administered by short-time continuous infusion (1 microg/kg/min for 5 min and 2 microg/kg/min for 5 min) followed by bolus injection (5 microg/kg). Hemodynamic responses were continuously measured using a right heart catheter.Hemodynamic responses were continuously measured before, during and after administration of nicardipine using an RHC. SaO2 (saturation of arterial blood) and SPAO2 (saturation of pulmonary arterial blood) were measured to calculate cardiac output every 5 minutes.
Not applicable |
Not applicable |
Male and Female
Patients diagnosed as having PAH without left heart disease
PAH is defined by a resting mean pulmonary artery pressure (PAP) 25 mmHg and more during right heart catheterization (RHC) with a mean pulmonary capillary wedge pressure (PCWP) 15 mmHg and less.
Exclusion criteria were as follows: thromboembolic pulmonary hypertension, hemodynamic instability including cardiac index less than 2.2 L/min/m2 and systolic blood pressure less than 80mmHg, or having symptoms associated with low cardiac output at rest.
100
1st name | |
Middle name | |
Last name | Nakamura Kazufumi |
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Department of Cardiovascular Medicine
2-5-1 Kita-ku, Shikata-cho, Okayama
0862357351
ichibun@cc.okayama-u.ac.jp
1st name | |
Middle name | |
Last name | Nakamura Kazufumi |
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Department of Cardiovascular Medicine
2-5-1 Kita-ku, Shikata-cho, Okayama
0862357351
ichibun@cc.okayama-u.ac.jp
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Self funding
Japan
National Hospital Organization, Okayama Medical Center
NO
岡山大学病院、岡山医療センター
2015 | Year | 12 | Month | 28 | Day |
Published
Main results already published
1999 | Year | 04 | Month | 01 | Day |
1999 | Year | 04 | Month | 01 | Day |
2015 | Year | 12 | Month | 28 | Day |
2015 | Year | 12 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023540
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |